drugset / Trial / NCT07628595
Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma
Phase 0
Not yet recruiting
19 enrolled
The First Affiliated Hospital with Nanjing Medical University
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetics, pharmacodynamics and immunogenicity of RN9101 injection for patients with relapsed/refractory multiple myeloma.
Timeline
- Start
- 2026-07-01
- Primary completion
- 2027-12-31
- Completion
- 2028-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RN9101 | Unknown | — | Intravenous |